Economic data for LTGO
Full calendarRecently released
- TodayUSDCore CPI m/m●●●Forecast 0.2%Previous 0.3%
- TodayUSDCPI●●●Forecast 338.683Previous 336.298
- TodayUSDCPI m/m●●●Forecast 0.5%Previous 0.6%
- TodayUSDCore CPI n.s.a. m/m●●●Previous 0.4%
- TodayUSDCore CPI●●●Forecast 339.796Previous 338.896
- TodayUSDCore CPI y/y●●●Forecast 2.8%Previous 2.6%
- TodayUSDCPI y/y●●●Forecast 4.2%Previous 3.7%
Coming up
- November 12, 2026USDInitial Jobless Claims●●●in 1 day
- November 12, 2026USDEIA Crude Oil Stocks Change●●●in 2 days
- November 13, 2026USDCore PPI m/m●●●Forecast 0.4%Previous 0.7%in 2 days
- November 13, 2026USDPPI m/m●●●Forecast 0.4%Previous 1.3%in 2 days
- November 17, 2026USDCore Retail Sales m/m●●●Forecast 0.7%Previous 0.9%in 6 days
- November 17, 2026USDRetail Sales m/m●●●Forecast 0.3%Previous 0.8%in 6 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
Both worlds over time
Technical and news signals of the last 90 days on one timeline.
LTGO fundamental outlook
From news analysis — different time windows than the trading horizons above · as of 10.09.2026
- Goldman Sachs initiated coverage with a Bullish rating and a $73 price target, citing the de-risked NaV1.8 inhibitor class and strong Phase 2b data for onzotrigine.
- LTGO completed an upsized IPO on August 7, 2026, raising $345.6 million, indicating strong institutional demand.
- The lead drug candidate, onzotrigine (LTG-001), is a non-opioid pain therapy with a major catalyst in the initiation of Phase 3 trials during the second half of 2026.
- Vertex's Journavx has validated the NaV1.8 mechanism, reducing clinical development risk for Latigo's pipeline.
- A primary clinical risk is the potential for a high placebo response on subjective pain endpoints in upcoming Phase 3 trials.
- The stock edged higher on its first day of trading, confirming that market demand exceeded the IPO offer price.
Latigo Biotherapeutics (LTGO) has entered the public markets with strong momentum, completing an upsized IPO that raised $345.6 million on August 7, 2026, signaling robust institutional demand for its non-opioid pain therapies. The stock edged higher on its debut, reflecting positive market reception. The investment thesis has since been reinforced by a September 8 Goldman Sachs initiation with a Bullish rating and a $73 price target, highlighting the commercial potential of lead candidate onzotrigine (LTG-001). The analyst note points to de-risking of the NaV1.8 inhibitor class by Vertex's Journavx and strong Phase 2b abdominoplasty trial results as key value drivers. The primary catalysts ahead are the initiation of Phase 3 trials for onzotrigine in the second half of 2026, with pivotal data readouts expected in the second half of 2027. Key risks include the inherent clinical uncertainty of subjective pain endpoints and potential placebo response, as well as competition from entrenched, low-cost generic opioids. The consistent Bullish sentiment across all three signals, with high confidence scores and significant impact ratings, paints a coherent picture of a newly public biotech company with a validated mechanism of action and a clear, near-term catalyst path.
61 days ago · Based on 3 signals
📝 Overview Generated automatically
LTGO has been the subject of 3 signals across 3 articles in the last 365 days. Sentiment skews Bullish (100%).
Breakdown: 3 bullish, 0 bearish, 0 neutral.
Most-cited catalysts: IPO raised $345.6 million (1×), Growing demand for non-opioid pain treatments (1×), Latigo completed an upsized IPO, suggesting strong institutional demand. (1×). Most-cited risk factors: Possible clinical trial failures (1×), Competition from established pain drug portfolios (1×), IPO gains may fade as lock-up periods expire. (1×).